drugset / Trial / NCT05948566
Strategy for Improving Stroke Treatment Response
Phase 2
Recruiting
300 enrolled
Translational Sciences, Inc.
Medical University of South Carolina · collabNational Institute of Neurological Disorders and Stroke (NINDS) · collabUniversity of Arizona · collabUniversity of Cincinnati · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in acute ischemic stroke.
Timeline
- Start
- 2024-03-18
- Primary completion
- 2027-07
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TS23 | Monoclonal antibody | — | — |